Optimal Data Collection Period for Continuous Glucose Monitoring to Assess Long-Term Glycemic Control: Revisited

2022 ◽  
pp. 193229682110691
Author(s):  
Simon Lebech Cichosz ◽  
Morten Hasselstrøm Jensen ◽  
Ole Hejlesen

Background and Objective: It is not clear how the short-term continuous glucose monitoring (CGM) sampling time could influence the bias in estimating long-term glycemic control. A large bias could, in the worst case, lead to incorrect classification of patients achieving glycemic targets, nonoptimal treatment, and false conclusions about the effect of new treatments. This study sought to investigate the relation between sampling time and bias in the estimates. Methods: We included a total of 329 type 1 patients (age 14-86 years) with long-term CGM (90 days) data from three studies. The analysis calculated the bias from estimating long-term glycemic control based on short-term sampling. Time in range (TIR), time above range (TAR), time below range (TBR), correlation, and glycemic target classification accuracy were assessed. Results: A sampling time of ten days is associated with a high bias of 10% to 47%, which can be reduced to 4.9% to 26.4% if a sampling time of 30 days is used ( P < .001). Correct classification of patients archiving glycemic targets can also be improved from 81.5% to 91.9 to 90% to 95.2%. Conclusions: Our results suggest that the proposed 10-14 day CGM sampling time may be associated with a high correlation with three-month CGM. However, these estimates are subject to large intersubject bias, which is clinically relevant. Clinicians and researchers should consider using assessments of longer durations of CGM data if possible, especially when assessing time in hypoglycemia or while testing a new treatment.

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 878-P
Author(s):  
KATHERINE TWEDEN ◽  
SAMANWOY GHOSH-DASTIDAR ◽  
ANDREW D. DEHENNIS ◽  
FRANCINE KAUFMAN

2011 ◽  
Vol 5 (6) ◽  
pp. 1472-1479 ◽  
Author(s):  
Jenny Anderson ◽  
Stig Attvall ◽  
Lennart Sternemalm ◽  
Aldina Pivodic ◽  
Martin Fahlén ◽  
...  

2019 ◽  
Vol 252 ◽  
pp. 02012
Author(s):  
Monika Klimek ◽  
Tytus Tulwin

Despite the progress we have made in the management of diabetes it is still incurable and aggravating disease affecting all domains of quality of life. Uncontrolled diabetes associated with hyperglycemia leads to serious microvascular and macrovascular long-term complications. The proper long-term glycemic control is a key strategy for preventing the development or slowing the progression of diabetes complications, thus there is a crucial role of new technologies in the diabetes care. New technologies in diabetology are developing dynamically in recent years and therefore this is a topical issue. In this paper we describe current and developing continuous glucose monitoring technologies and their usefulness in promoting optimal glycemic control, influence on personalized diabetes managements and the functioning of patients. Moreover we review knowledge about flash glucose monitoring and close-loop system. This review examines studies published before 31st August 2018.


2011 ◽  
Vol 13 (3) ◽  
pp. 351-358 ◽  
Author(s):  
Dongyuan Xing ◽  
Craig Kollman ◽  
Roy W. Beck ◽  
William V. Tamborlane ◽  
Lori Laffel ◽  
...  

2018 ◽  
Vol 20 (4) ◽  
pp. 314-316 ◽  
Author(s):  
Tonya D. Riddlesworth ◽  
Roy W. Beck ◽  
Robin L. Gal ◽  
Crystal G. Connor ◽  
Richard M. Bergenstal ◽  
...  

2018 ◽  
Vol 20 (9) ◽  
pp. 628-631 ◽  
Author(s):  
Ryo Shibusawa ◽  
Eijiro Yamada ◽  
Shuichi Okada ◽  
Yasuyo Nakajima ◽  
Claire C. Bastie ◽  
...  

2020 ◽  
Author(s):  
Pamela R. Kushner ◽  
Davida F. Kruger

Continuous glucose monitoring (CGM) provides comprehensive assessment of daily glucose measurements for patients with diabetes and can reveal high and low blood glucose values that may occur even when a patient’s A1C is adequately controlled. Among the measures captured by CGM, the percentage of time in the target glycemic range, or “time in range,” (typically 70–180 mg/dL) has emerged as one of the strongest indicators of good glycemic control. This review examines the shift to using CGM to assess glycemic control and guide diabetes treatment decisions, with a focus on time in range as the key metric of glycemic control.


2020 ◽  
Author(s):  
Pamela R. Kushner ◽  
Davida F. Kruger

Continuous glucose monitoring (CGM) provides comprehensive assessment of daily glucose measurements for patients with diabetes and can reveal high and low blood glucose values that may occur even when a patient’s A1C is adequately controlled. Among the measures captured by CGM, the percentage of time in the target glycemic range, or “time in range,” (typically 70–180 mg/dL) has emerged as one of the strongest indicators of good glycemic control. This review examines the shift to using CGM to assess glycemic control and guide diabetes treatment decisions, with a focus on time in range as the key metric of glycemic control.


Sign in / Sign up

Export Citation Format

Share Document